MIFH
Migdal Insurance & Financial Holdings Portfolio holdings
AUM
$8.42B
1-Year Return
18.65%
This Quarter Return
+20.27%
1 Year Return
+18.65%
3 Year Return
+96.52%
5 Year Return
+186.2%
10 Year Return
–
AUM
$8.47B
AUM Growth
+$1.27B
(+18%)
Cap. Flow
+$82.5M
Cap. Flow
% of AUM
0.97%
Top 10 Holdings %
Top 10 Hldgs %
39.44%
Holding
764
New
106
Increased
151
Reduced
309
Closed
117
Top Buys
| 1 |
iShares Russell 2000 ETF
IWM
|
+$218M |
| 2 |
SPDR S&P Bank ETF
KBE
|
+$177M |
| 3 |
Health Care Select Sector SPDR Fund
XLV
|
+$84.7M |
| 4 |
Amazon
AMZN
|
+$76.4M |
| 5 |
Invesco S&P 500 Equal Weight Consumer Discretionary ETF
RSPD
|
+$55M |
Top Sells
| 1 |
KraneShares CSI China Internet ETF
KWEB
|
+$87.5M |
| 2 |
iShares US Medical Devices ETF
IHI
|
+$69.4M |
| 3 |
iShares US Home Construction ETF
ITB
|
+$40.7M |
| 4 |
Equinix
EQIX
|
+$36M |
| 5 |
US Global Jets ETF
JETS
|
+$35.8M |
Sector Composition
| 1 | Technology | 21.75% |
| 2 | Financials | 9.43% |
| 3 | Consumer Discretionary | 9.03% |
| 4 | Communication Services | 6.41% |
| 5 | Healthcare | 3.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Passage Bio
PASG
$22.3M
| $274K | ﹤0.01% |
+536
| New | +$274K |
|
277
Myriad Genetics
MYGN
$674M
| $273K | ﹤0.01% |
+13,782
| New | +$273K |
|
278
Guardant Health
GH
$6.85B
| $272K | ﹤0.01% |
+2,109
| New | +$272K |
|
|
GNMK
279
DELISTED
GenMark Diagnostics, Inc
GNMK
| $272K | ﹤0.01% |
+18,659
| New | +$272K |
|
280
Invesco S&P 500 Low Volatility ETF
SPLV
$7.9B
| $270K | ﹤0.01% |
4,820
-6,623
| -58% | -$371K |
|
281
Vertex Pharmaceuticals
VRTX
$101B
| $270K | ﹤0.01% |
+1,142
| New | +$270K |
|
282
TAL Education Group
TAL
$6.67B
| $268K | ﹤0.01% |
3,754
+1,585
| +73% | +$113K |
|
|
TECX
283
Tectonic Therapeutic, Inc. Common Stock
TECX
$332M
| $268K | ﹤0.01% |
+1,601
| New | +$268K |
|
284
Ciena
CIEN
$18.6B
| $267K | ﹤0.01% |
5,058
+1,821
| +56% | +$96.1K |
|
285
Invesco MSCI Sustainable Future ETF
ERTH
$143M
| $261K | ﹤0.01% |
3,480
+1,380
| +66% | +$104K |
|
286
Exact Sciences
EXAS
$10.2B
| $261K | ﹤0.01% |
1,969
-8,203
| -81% | -$1.09M |
|
287
Alnylam Pharmaceuticals
ALNY
$61.1B
| $255K | ﹤0.01% |
+1,962
| New | +$255K |
|
|
VLDR
288
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
| $253K | ﹤0.01% |
+11,080
| New | +$253K |
|
289
Black Diamond Therapeutics
BDTX
$185M
| $253K | ﹤0.01% |
+7,881
| New | +$253K |
|
290
Standard BioTools
LAB
$493M
| $252K | ﹤0.01% |
+42,043
| New | +$252K |
|
291
10x Genomics
TXG
$1.57B
| $251K | ﹤0.01% |
1,772
-10,630
| -86% | -$1.51M |
|
292
Regeneron Pharmaceuticals
REGN
$59.4B
| $249K | ﹤0.01% |
+516
| New | +$249K |
|
|
LMNX
293
DELISTED
Luminex Corp
LMNX
| $247K | ﹤0.01% |
+10,681
| New | +$247K |
|
294
Las Vegas Sands
LVS
$36.7B
| $246K | ﹤0.01% |
4,123
-42,584
| -91% | -$2.54M |
|
295
PTC Therapeutics
PTCT
$4.85B
| $245K | ﹤0.01% |
+4,011
| New | +$245K |
|
296
Delta Air Lines
DAL
$39.1B
| $240K | ﹤0.01% |
5,968
-73,029
| -92% | -$2.94M |
|
|
CLLS
297
Cellectis
CLLS
$290M
| $238K | ﹤0.01% |
+8,812
| New | +$238K |
|
298
Hilton Worldwide
HLT
$64.6B
| $238K | ﹤0.01% |
2,137
-177,863
| -99% | -$19.8M |
|
|
BLUE
299
DELISTED
bluebird bio
BLUE
| $237K | ﹤0.01% |
+423
| New | +$237K |
|
300
Alaunos Therapeutics
TCRT
$5.1M
| $236K | ﹤0.01% |
+624
| New | +$236K |
|